A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active:	No
Cancer Type:	Colon/Rectal Cancer Unknown Primary	NCT ID:	NCT05723562
Trial Phases:	Phase II	Protocol IDs:	219369 (primary) NCI-2023-04062 2022-003289-18
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	GlaxoSmithKline
NCI Full Details:	http://clinicaltrials.gov/show/NCT05723562

Summary

The purpose of this study is to investigate dostarlimab monotherapy in participants with
locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H)
rectal cancer who have received no prior treatment. Participants who achieve complete
clinical response (cCR) following dostarlimab treatment will undergo non-operative
management (NOM), including close surveillance for recurrent disease. The goal of the
study is to determine if Dostarlimab therapy alone is an effective treatment that can
allow participants to avoid chemotherapy, radiation, and surgery.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.